MONJUVI (tafasitamab-cxix) for injection
MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL). Brand Name: MONJUVI (tafasitamab-cxix) for injection, for intravenous use Initial U.S. Approval: 2020
Home | tafasitamab-cxix for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
MONJUVI (tafasitamab-cxix) for injection, for intravenous use
Tafasitamab-cxix is approved to treat: Diffuse large B-cell lymphoma (certain types) that has relapsed (come back) or is refractory (does not respond to treatment). It is used with lenalidomide in adults who cannot receive an autologous stem cell transplant.
MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Tafasitamab is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
Tafasitamab was approved for medical use in the United States in July 2020, and in the European Union in August 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Drug (Brand / Generic): MONJUVI / tafasitamab-cxix
Current Indications: Diffuse large B-cell lymphoma
Marketed by:: MORPHOSYS US INC
Approval Date: 2020
Dosage forms and strengths of ALUNBRIG (brigatinib).
Tablets: 180 mg, 90 mg, or 30 mg.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “MONJUVI (tafasitamab-cxix) for injection”.
Confirmation of the order for MONJUVI (tafasitamab-cxix) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand MONJUVI (tafasitamab-cxix) for injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to MONJUVI (tafasitamab-cxix) for injection, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for MONJUVI (tafasitamab-cxix) for injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.